SNY
Sanofi
$46.78
-$0.75(-1.58%)
63
Overall
100
Value
36
Tech
55
Quality
Market Cap
$116.19B
Volume
2.93M
52W Range
$43.32 - $55.73
Target Price
$55.44
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $35.1B | $38.8B | $36.1B | $36.0B | $37.7B | $43.0B | -- | $44.3B | $46.7B | ||
| Total Revenue | $34.9B | $38.8B | $36.1B | $37.4B | $39.2B | $45.4B | -- | $44.3B | $46.7B | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | $-11.6B | $11.4B | $12.0B | $12.2B | $12.3B | $13.7B | -- | $13.2B | $13.0B | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $24.6B | $27.3B | $24.1B | $25.2B | $26.9B | $31.7B | -- | $31.1B | $33.7B | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $19.5B | $19.9B | $23.7B | $18.2B | $18.6B | $19.8B | -- | $23.0B | $27.1B | ||
| Research & Development | $5.5B | $5.9B | $6.0B | $5.5B | $5.7B | $6.7B | -- | $7.4B | $7.8B | ||
| Research Expense | $5.5B | $5.9B | $6.0B | $5.5B | $5.7B | $6.7B | -- | $7.4B | $7.8B | ||
| Selling, General & Administrative | $10.1B | $9.8B | $9.9B | $9.7B | $9.6B | $10.9B | -- | $9.2B | $9.5B | ||
| Selling & Marketing Expenses | $10.1B | $9.8B | $9.9B | $9.7B | $9.6B | $10.5B | -- | $9.2B | $9.5B | ||
| General & Administrative Expenses | -- | $435.0M | $-47.0M | $64.0M | $4.0M | $440.0M | -- | -- | -- | ||
| Salaries & Wages | $1.4B | $1.6B | $4.1B | $-136.0M | $5.0M | $370.0M | -- | -- | -- | ||
| Depreciation & Amortization | $2.3B | $2.2B | $2.5B | $1.7B | $1.6B | $2.1B | -- | $2.0B | $4.0B | ||
| Depreciation & Amortization | $2.3B | $2.2B | $2.5B | $1.7B | $1.6B | $2.1B | -- | $2.0B | $4.0B | ||
| Amortization | $1.9B | $2.2B | $2.5B | $1.7B | $1.6B | $2.1B | -- | $2.0B | $4.0B | ||
| Other Operating Expenses | $233.0M | $548.0M | $1.2B | $1.4B | $1.8B | $2.5B | -- | $4.4B | $5.7B | ||
| OPERATING INCOME | |||||||||||
| Operating income | $3.7B | $7.4B | $460.0M | $5.6B | $6.9B | $6.7B | -- | $8.1B | $6.6B | ||
| EBITDA | $17.3B | $16.8B | $7.0B | $17.9B | $11.5B | $14.3B | -- | $11.4B | $12.3B | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $434.0M | $389.0M | $461.0M | -- | $1.1B | $563.0M | ||
| Interest Income Operating | -- | $72.0M | $92.0M | $37.0M | $6.2B | $118.0M | -- | $1.1B | $1.2B | ||
| Intinc | $8.6B | $164.0M | $169.0M | $53.0M | $40.0M | $206.0M | -- | $519.0M | $394.0M | ||
| Net Non-Operating Interest Income/Expense | $8.7B | $164.0M | $169.0M | $53.0M | $40.0M | $288.0M | -- | $-554.0M | $-169.0M | ||
| Gain on Sale of Securities | -- | -- | -- | $7.4B | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-5.8B | $-5.8B | $-6.5B | $-15.8B | $-15.8B | $-1.2B | -- | $506.0M | $514.0M | ||
| Other Special Charges | $33.0M | $24.0M | $2.1B | $5.3B | $6.2B | $992.0M | -- | $-470.0M | $-255.0M | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | $-731.0M | $-1.5B | $-1.1B | $1.1B | $820.0M | $1.3B | -- | $1.4B | $1.1B | ||
| Special Income Charges | $985.0M | $-435.0M | $-331.0M | $10.9B | $-694.0M | $-777.0M | -- | $-1.4B | $-1.1B | ||
| Impairment of Capital Assets | $-254.0M | $-94.0M | $444.0M | $330.0M | $-494.0M | $-559.0M | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $15.0B | $14.6B | $4.9B | $14.2B | $8.2B | $10.9B | -- | $7.8B | $6.6B | ||
| Pre-Tax Income | $15.0B | $14.3B | $7.6B | $28.4B | $24.6B | $10.4B | -- | $6.8B | $6.0B | ||
| INCOME TAX | |||||||||||
| Tax Provision | $1.7B | $481.0M | $139.0M | $1.8B | $1.6B | $2.0B | -- | $1.2B | $1.0B | ||
| NET INCOME | |||||||||||
| Net Income | $18.1B | $13.9B | $7.4B | $12.3B | $6.2B | $8.4B | -- | $5.6B | $7.8B | ||
| Net Income (Continuing Operations) | $18.1B | $13.9B | $7.4B | $26.6B | $23.0B | $8.5B | -- | $5.6B | $5.0B | ||
| Net Income (Discontinued Operations) | $18.1B | $13.9B | $7.4B | $12.3B | $6.2B | $8.4B | -- | $5.6B | $7.8B | ||
| Net Income (Common Stockholders) | $18.1B | $13.9B | $7.4B | $12.3B | $6.2B | $8.4B | -- | $5.6B | $7.8B | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $8.1B | $7.1B | ||
| TOTALS | |||||||||||
| Total Expenses | $7.9B | $31.4B | $35.7B | $30.4B | $30.9B | $33.5B | -- | $36.2B | $40.1B | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $1.3B | $2.5B | -- | ||
| Average Shares Outstanding (Diluted) | $1.3B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $1.3B | $2.5B | -- | ||
| Shares Outstanding | $1.3B | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B | -- | $2.4B | $1.2B | ||
| Basic EPS | $3.35 | $3.46 | $2.29 | $9.82 | $2.48 | -- | $4.31 | $2.22 | -- | ||
| Basic EPS (Continuing Operations) | $3.35 | $3.46 | $2.29 | $9.82 | $2.48 | -- | $4.31 | $2.22 | -- | ||
| Diluted EPS | $3.33 | $3.44 | $2.27 | $9.77 | $2.48 | -- | $4.3 | $2.21 | -- | ||
| Diluted EPS (Continuing Operations) | $3.33 | $3.44 | $2.27 | $9.77 | $2.48 | -- | $4.3 | $2.21 | -- | ||
| Dividend Per Share | $1.791 | -- | $1.699 | -- | -- | $3.91 | $3.76 | $1.88 | -- | ||
| OTHER METRICS | |||||||||||
| Acquired In Process Rn D | -- | -- | -- | $12.3B | -- | -- | -- | -- | -- | ||
| Acquired In Process Rn D Income | -- | $5.3B | -- | $8.3B | $9.5B | $11.1B | -- | -- | -- | ||
| Acquisition Expense | -- | -- | $-47.0M | -- | -- | -- | -- | -- | -- | ||
| Allowances For Construction | -- | -- | -- | $267.0M | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | $85.0M | $499.0M | $3.7B | $8.7B | $106.0M | $68.0M | -- | $60.0M | $-155.0M | ||
| Earnings From Equity Interest Net Of Tax | $85.0M | $499.0M | $3.7B | $8.7B | $106.0M | $68.0M | -- | $60.0M | $-155.0M | ||
| Excise Taxes | $137.0M | -- | -- | $39.0M | -- | -- | -- | -- | -- | ||
| Fees | -- | -- | -- | -- | $78.0M | -- | -- | -- | -- | ||
| Gain On Sale Of Business | $5.8B | $-4.0M | -- | -- | -- | $8.4B | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | $162.0M | $2.8B | -- | $9.5B | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | $4.6B | $-13.0M | $-101.0M | -- | -- | -- | -- | -- | -- | ||
| Insurance And Claims | -- | -- | $-47.0M | $64.0M | $4.0M | $440.0M | -- | -- | -- | ||
| Interest Expense Operating | -- | $313.0M | $826.0M | $-315.0M | $-686.0M | $-654.0M | -- | -- | -- | ||
| Loss And Loss Adjustment Expected Incurred | -- | $-201.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Marketing Expense | -- | -- | -- | $-124.0M | -- | -- | -- | -- | -- | ||
| Minority Interests | $121.0M | $104.0M | $31.0M | $-36.0M | $-56.0M | $-113.0M | -- | $-58.0M | $-38.0M | ||
| Net Income Discontinuous Operations | $4.6B | $-13.0M | $-101.0M | $-35.0M | $-4.0M | -- | -- | $64.0M | $2.9B | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | -- | $13.2B | $13.0B | ||
| Other Gand A | -- | $435.0M | $-47.0M | $64.0M | $4.0M | $440.0M | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $216.0M | -- | -- | -- | ||
| Realized Capital Gain | -- | -- | $30.0M | $16.0M | -- | -- | -- | -- | -- | ||
| Selling Expense | $10.1B | $9.9B | $9.9B | $9.8B | $9.6B | $10.5B | -- | -- | -- | ||
| Write Down | -- | -- | $-113.0M | -- | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | $435.0M | -- | $63.0M | $368.0M | -- | -- | -- | -- | ||
| Restruct | $-731.0M | $-1.5B | $-1.1B | $1.1B | $820.0M | $1.3B | -- | $1.4B | $1.1B | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SNY | $46.78 | -1.6% | 2.93M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |